BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iadademstat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Iadademstat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06502145-2924@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iadademstat: Phase 1 readout est. (NCT06502145)
DESCRIPTION:Iadademstat\, phase 1.\nStudy: Iadademstat With Hypomethylating
  Agent in Patients With Myelodysplastic Syndrome\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iadademstat#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06502145
URL:https://assetmemo.bio/drug/iadademstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357182-2924@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Iadademstat: Phase 1 readout est. (NCT06357182)
DESCRIPTION:Iadademstat\, phase 1\, Acute Myeloid Leukemia.\nStudy: Iadadem
 stat in Combination With Azacitidine and Venetoclax in Treating Newly Diag
 nosed Acute Myeloid Leukemia\nEstimated primary completion: 8 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/iadademstat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06357182
URL:https://assetmemo.bio/drug/iadademstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06661915-2924@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iadademstat: Phase 2 readout est. (NCT06661915)
DESCRIPTION:Iadademstat\, phase 2.\nStudy: A Randomized Study of ASTX727 Wi
 th or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iadademstat#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06661915
URL:https://assetmemo.bio/drug/iadademstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287775-2924@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:Iadademstat: Phase 1/2 readout est. (NCT06287775)
DESCRIPTION:Iadademstat\, phase 1/2.\nStudy: Testing the Combination of an 
 Anti-cancer Drug\, Iadademstat\, With Other Anti-cancer Drugs (Atezolizuma
 b or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer\nEstimat
 ed primary completion: 25 July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/iadademstat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06287775
URL:https://assetmemo.bio/drug/iadademstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113691-2924@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Iadademstat: Phase 1 readout est. (NCT07113691)
DESCRIPTION:Iadademstat\, phase 1.\nStudy: Iadademstat + SBRT With Atezo in
  ES-SCLC\nEstimated primary completion: January 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/iadademstat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07113691
URL:https://assetmemo.bio/drug/iadademstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
